FDA Drug Recalls
18,003 recalls, newest first
Apr 26, 2023
Class I · High risk
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Apr 26, 2023
Class I · High risk
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.
Apr 26, 2023
Class II · Moderate risk
Presence of Foreign Substance: Glass splinter particle entrapped inside the pump ball seat rendered the pump inoperable.
Apr 24, 2023
Class III · Low risk
Product mixup: one foreign tablet found in product.
Apr 20, 2023
Class I · High risk
Product mix-up: incorrect product was found inside the G-Supress DX product carton.
Apr 20, 2023
Class III · Low risk
Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains.
Apr 19, 2023
Class II · Moderate risk
Presence of Particulate Matter: A piece of glass was found in a prefilled syringe.
Apr 19, 2023
Class II · Moderate risk
Superpotent Drug and Failed Impurities/Degradation Products: formula does not adhere to the labeled specifications
Apr 13, 2023
Class III · Low risk
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Apr 13, 2023
Class III · Low risk
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Apr 13, 2023
Class III · Low risk
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Apr 13, 2023
Class III · Low risk
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Apr 13, 2023
Class II · Moderate risk
Lack of assurance of sterility.
Apr 11, 2023
Class II · Moderate risk
Lack of Assurance of Sterility: Malformed crimped collar seal
Apr 10, 2023
Class III · Low risk
Subpotent Drug: Out of specification results for low potency was obtained.
Apr 7, 2023
Class II · Moderate risk
CGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.
Apr 6, 2023
Class II · Moderate risk
Apr 6, 2023
Class II · Moderate risk
Apr 6, 2023
Class II · Moderate risk
Apr 6, 2023
Class II · Moderate risk
Apr 6, 2023
Class II · Moderate risk
Apr 6, 2023
Class II · Moderate risk
CGMP Deviations: active ingredient may be subpotent before the labeled expiry due to degradation.
Mar 31, 2023
Class II · Moderate risk
CGMP deviation: product outside labeled storage temperature requirements.
Mar 31, 2023
Class II · Moderate risk
CGMP deviation: product outside labeled storage temperature requirements.
Mar 31, 2023
Class II · Moderate risk
CGMP deviation: product outside labeled storage temperature requirements.